Skip to content

Sensient Technologies

US · SXT #2027 by market cap Listed 1970
113.85 -2.58 -2.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $143
    Market Newswire · 2026/7/6
  • UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $157
    Market Newswire · 2026/9/30
  • Rating change
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $125
    Market Newswire · 2025/7/4
  • Company notice
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.
    SEC · 2023/3/30
  • China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
    PR Newswire · 2026/10/8
  • Company notice
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.
    SEC · 2022/8/26
  • Rating change
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $140
    Market Newswire · 2026/7/27
  • China SXT Pharmaceuticals Announces 1-For-100 Reverse Stock Split, Effective Oct. 26
    Benzinga · 2026/10/22
  • Company notice
    China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(0%),Streeterville Management LLC(0%), etc.
    SEC · 2023/3/30
  • Rating change
    Rothschild & Co Redburn Initiates Sensient Technologies(SXT.US) With Hold Rating, Announces Target Price $125
    Market Newswire · 2026/7/8
  • Company notice
    China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(9.99%),Streeterville Management LLC(9.99%), etc.
    SEC · 2024/10/26
  • Rating change
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $93
    Market Newswire · 2025/4/29
  • UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $154
    Market Newswire · 2026/11/2
  • GUIDANCE: (SXT) Sensient Technologies Expects 2026 EPS Range $4.15 - $4.20, Vs. FactSet Est of $4.20
    MT Newswires · 2026/10/30
  • Company notice
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Fund II LLC(9.9%), etc.
    SEC · 2022/1/22
  • Rating change
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $85
    Market Newswire · 2024/10/28
  • Rating change
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $85
    Market Newswire · 2024/7/29
  • Rating change
    UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $155
    Market Newswire · 2026/7/27
  • Rating change
    UBS Initiates Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $115
    Market Newswire · 2026/4/1
  • Rating change
    UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $143
    Market Newswire · 2026/4/28
  • Rating change
    Baird: Maintaining the Sensient Technologies (SXT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $70.00 to $80.00.
    Zhitong Finance · 2024/4/29

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Sensient Technologies discussion 0 comments

Add a comment